BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 23391836)

  • 21. Predictive value of quantitative diffusion-weighted imaging and 18-F-FDG-PET in head and neck squamous cell carcinoma treated by (chemo)radiotherapy.
    Martens RM; Noij DP; Koopman T; Zwezerijnen B; Heymans M; de Jong MC; Hoekstra OS; Vergeer MR; de Bree R; Leemans CR; de Graaf P; Boellaard R; Castelijns JA
    Eur J Radiol; 2019 Apr; 113():39-50. PubMed ID: 30927958
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Can 3'-Deoxy-3'-((18)F) Fluorothymidine Out Perform 2-Deoxy-2-((18)F) Fluoro-D-Glucose Positron Emission Tomography/Computed Tomography in the Diagnosis of Cervical Lymphadenopathy in Patients With Oral/Head and Neck Cancer?
    Schaefferkoetter JD; Carlson ER; Heidel RE
    J Oral Maxillofac Surg; 2015 Jul; 73(7):1420-8. PubMed ID: 25869746
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The nodal standard uptake value (SUV) as a prognostic factor in head and neck squamous cell cancer.
    Demirci U; Coskun U; Akdemir UO; Benekli M; Kapucu O; Ozkan S; Cakir T; Baykara M; Buyukberber S
    Asian Pac J Cancer Prev; 2011; 12(7):1817-20. PubMed ID: 22126572
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Utility of SUV
    Lim RS; Ramdave S; Beech P; Billah B; Karim MN; Smith JA; Safdar A; Sigston E
    Cancer Imaging; 2016 Nov; 16(1):39. PubMed ID: 27821180
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neck dissection can be avoided after sequential chemoradiotherapy and negative post-treatment positron emission tomography-computed tomography in N2 head and neck squamous cell carcinoma.
    Loo SW; Geropantas K; Beadsmoore C; Montgomery PQ; Martin WM; Roques TW
    Clin Oncol (R Coll Radiol); 2011 Oct; 23(8):512-7. PubMed ID: 21501953
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of fluoro-2-deoxy-D-glucose positron emission tomography to evaluate responses to concurrent chemoradiotherapy for head and neck squamous cell carcinoma.
    Mori M; Tsukuda M; Horiuchi C; Matsuda H; Taguchi T; Takahashi M; Nishimura G; Komatsu M; Niho T; Sakuma N; Shibata K; Sugisaki S
    Auris Nasus Larynx; 2011 Dec; 38(6):724-9. PubMed ID: 21665394
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Correlation between fluorodeoxyglucose hotspots on pretreatment positron emission tomography/CT and preferential sites of local relapse after chemoradiotherapy for head and neck squamous cell carcinoma.
    Chaput A; Calais J; Robin P; Thureau S; Bourhis D; Modzelewski R; Schick U; Vera P; Salaün PY; Abgral R
    Head Neck; 2017 Jun; 39(6):1155-1165. PubMed ID: 28263422
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adherence to pretreatment and intratreatment imaging of head and neck squamous cell carcinoma patients undergoing (chemo) radiotherapy in a research setting.
    Martens RM; Koopman T; Noij DP; de Bree R; Vergeer MR; Zwezerijnen G; Leemans CR; de Graaf P; Boellaard R; Castelijns JA
    Clin Imaging; 2021 Jan; 69():82-90. PubMed ID: 32693228
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of changes in maximum standardized uptake value of FDG PET-CT for post-treatment surveillance in patients with head and neck squamous cell carcinoma treated with chemoradiotherapy: preliminary findings.
    Matoba M; Tuji H; Shimode Y; Kondo T; Oota K; Tonami H
    Br J Radiol; 2017 Mar; 90(1071):20150404. PubMed ID: 28055245
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Repeatability of 18F-FDG PET/CT in Advanced Non-Small Cell Lung Cancer: Prospective Assessment in 2 Multicenter Trials.
    Weber WA; Gatsonis CA; Mozley PD; Hanna LG; Shields AF; Aberle DR; Govindan R; Torigian DA; Karp JS; Yu JQ; Subramaniam RM; Halvorsen RA; Siegel BA; ;
    J Nucl Med; 2015 Aug; 56(8):1137-43. PubMed ID: 25908829
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of radiation dose and standardized uptake value of (18)FDG PET on nodal control in locally advanced cervical cancer.
    Ramlov A; Kroon PS; Jürgenliemk-Schulz IM; De Leeuw AA; Gormsen LC; Fokdal LU; Tanderup K; Lindegaard JC
    Acta Oncol; 2015; 54(9):1567-73. PubMed ID: 26271799
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early prediction of survival following induction chemotherapy with DCF (docetaxel, cisplatin, 5-fluorouracil) using FDG PET/CT imaging in patients with locally advanced head and neck squamous cell carcinoma.
    Abgral R; Le Roux PY; Keromnes N; Rousset J; Valette G; Gouders D; Leleu C; Mollon D; Nowak E; Querellou S; Salaün PY
    Eur J Nucl Med Mol Imaging; 2012 Dec; 39(12):1839-47. PubMed ID: 22895863
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Imaging strategy for response evaluation to chemoradiotherapy of the nodal disease in patients with head and neck squamous cell carcinoma.
    Nishimura G; Yabuki K; Hata M; Komatsu M; Taguchi T; Takahashi M; Shiono O; Sano D; Arai Y; Takahashi H; Chiba Y; Oridate N
    Int J Clin Oncol; 2016 Aug; 21(4):658-667. PubMed ID: 26710795
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ¹⁸F-FDG-PET imaging in radiotherapy tumor volume delineation in treatment of head and neck cancer.
    Delouya G; Igidbashian L; Houle A; Bélair M; Boucher L; Cohade C; Beaulieu S; Filion EJ; Coulombe G; Hinse M; Martel C; Després P; Nguyen-Tan PF
    Radiother Oncol; 2011 Dec; 101(3):362-8. PubMed ID: 21885143
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Influence of FDG-PET on primary nodal target volume definition for head and neck carcinomas.
    van Egmond SL; Piscaer V; Janssen LM; Stegeman I; Hobbelink MG; Grolman W; Terhaard CH
    Acta Oncol; 2016; 55(9-10):1099-1106. PubMed ID: 27219720
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Response evaluation of cervical lymph nodes after chemoradiation in patients with head and neck cancer - does additional [18F]FDG-PET-CT help?
    Dejaco D; Uprimny C; Widmann G; Riedl D; Moser P; Arnold C; Steinbichler TB; Kofler B; Schartinger VH; Virgolini I; Riechelmann H
    Cancer Imaging; 2020 Sep; 20(1):69. PubMed ID: 32993805
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [
    Vos JL; Zuur CL; Smit LA; de Boer JP; Al-Mamgani A; van den Brekel MWM; Haanen JBAG; Vogel WV
    Eur J Nucl Med Mol Imaging; 2022 May; 49(6):2010-2022. PubMed ID: 34957526
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recurrences after intensity modulated radiotherapy for head and neck squamous cell carcinoma more likely to originate from regions with high baseline [18F]-FDG uptake.
    Due AK; Vogelius IR; Aznar MC; Bentzen SM; Berthelsen AK; Korreman SS; Loft A; Kristensen CA; Specht L
    Radiother Oncol; 2014 Jun; 111(3):360-5. PubMed ID: 24993331
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of 18F-FDG PET/CT and CT/MRI with histopathologic correlation in patients undergoing salvage surgery for head and neck squamous cell carcinoma.
    Kim SY; Kim JS; Yi JS; Lee JH; Choi SH; Nam SY; Cho KJ; Lee SW; Kim SB; Roh JL
    Ann Surg Oncol; 2011 Sep; 18(9):2579-84. PubMed ID: 21409485
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Staging and Response Evaluation to Neo-Adjuvant Chemoradiation in Esophageal Cancers Using 18FDG PET/ CT with Standardized Protocol.
    Fatima N; Zaman MU; Zaman A; Zaman U; Tahseen R; Zaman S
    Asian Pac J Cancer Prev; 2019 Jul; 20(7):2003-2008. PubMed ID: 31350957
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.